Home > News > Biophan Executes Definitive Agreements with Boston Scientific
July 1st, 2005
Biophan Executes Definitive Agreements with Boston Scientific
Abstract:
Biophan Technologies, Inc., a developer of next-generation biomedical technology, today announced it has reached a definitive agreement with Boston Scientific Corporation on an equity investment and technology license. The equity transaction consists of the purchase of Biophan common stock totaling $5 million, priced at a 10% premium over the average of the closing price for the 30 calendar-day period prior to the closing. The technology license includes an upfront payment of $750,000 and annual maintenance fees, in addition to royalties and milestone payments.
Source:
biophan.com
Bookmark:
Investments/IPO's/Splits
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
Harris & Harris Group Notes the Sale of a Second D-Wave Quantum Computer May 16th, 2013
Nanometrics Announces Upcoming Investor Events May 14th, 2013
Nanomedicine
Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013
Microneedle-Delivered Nanoparticles Boost Antitumor Vaccines May 20th, 2013
New Nanopore Sensor Simplifies Analysis of Methylated DNA May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Announcements
Competition in the Quantum World May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Penn engineers' nanoantennas improve infrared sensing May 20th, 2013
Researchers Perform Fastest Measurements Ever Made of Ion Channel Proteins May 20th, 2013
Patents/IP/Tech Transfer/Licensing
NanoInk, Inc. Assets To Be Sold May 18th, 2013
HELIOS Program Develops Complete Supply Chain for Integrating Photonics with CMOS Circuit via IC Fabrication Processes May 14th, 2013
Nanotechnology Pioneer Named 'Entrepreneur of the Year': Royal Society of Chemistry honors Chad Mirkin for commercializing innovations May 10th, 2013
Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone May 7th, 2013